..... all smoke and mirrors ... no point adding this $10 million from Novaquest into the "Estimated Cash Available" when it is conditional upon the pediatric approval - that may not happen for 3-6 months.... so therefore they basically have this quarter and January to find capital from somewhere - $53M - $14M (Dec Quarter) = circa $39M less $35M minimum reserves = $4M left in Jan 2024
"An additional US$10.0 million from the loan will be drawn on marketing approval of remestemcel-L for the treatment in pediatric patients with steroid-refractory acute graft versus host disease"
..... all smoke and mirrors ... no point adding this $10 million...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.67 |
Change
0.015(0.91%) |
Mkt cap ! $2.133B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.67 | $1.63 | $3.655M | 2.203M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 48000 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 98565 | 7 |
View Market Depth
| Last trade - 16.10pm 14/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |